DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue disaggregation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue recognition	$ 316,385	$ 216,136	$ 208,475
Sales of generic pharmaceutical products
Revenue recognition	210,121	143,571	147,257
Sales of established brand pharmaceutical products
Revenue recognition	39,463	47,561	47,960
Sales of rare disease pharmaceutical products
Revenue recognition	41,686
Sales of contract manufactured products
Revenue recognition	16,106	10,042	9,221
Royalties from licensing agreements
Revenue recognition	5,367	11,795	1,396
Product development services
Revenue recognition	2,949	1,310	1,858
Other
Revenue recognition	$ 693	$ 1,857	$ 783